NVO
ACCE-researchedOverview
ACCE thesis
Novo Nordisk manufactures diabetes treatments including insulin and GLP-1 receptor agonists like Ozempic and Wegovy, which have exploded into blockbuster obesity medications generating $21 billion in 2023 sales. The company controls roughly half the global insulin market and owns the manufacturing infrastructure for GLP-1 drugs that competitors struggle to replicate at scale. Wegovy's launch in major European markets throughout 2024 creates a massive runway beyond the supply-constrained U.S. rollout. Trading at 11x earnings despite 60% ROE and 82% gross margins, the stock looks divorced from the obesity drug revolution it's leading. Supply constraints that hammered 2023 revenue are lifting as new production facilities come online in 2024.
- highMomentum score collapse riskACCE score surged +29 pts in 90 days (47→76), suggesting rapid re-rating; sharp reversals often follow such compressed recoveries.
- highForward P/E exceeds trailingForward P/E 14.7 vs trailing 11.9 implies earnings are expected to decline, contradicting the +67.1% YoY growth narrative.
- moderateSequential revenue decelerationQoQ revenue growth of -11.5% signals potential plateau despite strong 24% YoY headline; watch for GLP-1 demand normalization.
- moderateWeak momentum scoreMomentum sub-score of 32/100 is strikingly low vs Quality 96 and Value 86, indicating poor price action despite strong fundamentals.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
Valuation
INVESTORSix independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORThe full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROFollow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| NOVO-B.CO | Novo Nordisk B | $176.1B | 9.9 | 59.8% | 0.63 | 4.2% | - | Compare |
| GILD | Gilead Sciences Inc. Common Stock | $186.7B | - | -20.7% | 1.10 | 2.1% | - | Compare |
| PFE | Pfizer Inc. Common Stock | $158.1B | 36.5 | 5.0% | 0.74 | 6.2% | - | Compare |
| AMGN | Amgen Inc. Common Stock | $212.6B | 24.5 | 91.5% | 6.31 | 2.5% | - | Compare |
| BMY | Bristol-Myers Squibb Company Common Stock | $127.9B | 13.8 | 46.6% | 2.44 | 4.0% | - | Compare |
| AZN.L | AstraZeneca | $259.9B | 25.1 | 22.0% | 0.57 | 0.0% | - | Compare |
Sector report card
Where NVO ranks against its sector peers on each metric.
News and Record
Press releases mentioning this company
- GlobeNewswire•Sep 18, 2026Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)
- GlobeNewswire•Sep 14, 2026Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
- GlobeNewswire•Sep 7, 2026Novo Nordisk A/S - share repurchase programme
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.